文献速递肝病

对乙酰氨基酚(扑热息痛)使用与病毒性肝炎相关急性肝衰竭患者严重程度及结局的关联

Association of Acetaminophen (Paracetamol) Use With Severity and Outcomes in Patients With Viral Hepatitis-Associated Acute Liver Failure.
PubMed 文献 · Am J Gastroenterol · 2024-07-12

这项前瞻性多中心队列研究纳入356例病毒性肝炎相关急性肝衰竭或急性肝损伤患者,57.5%有对乙酰氨基酚使用证据,24%为高或中等暴露。高暴露组死亡率最高(51.6%)且无移植生存率最低(22.6%),但与无暴露组的具体比较未达统计学显著差异。作者认为对乙酰氨基酚使用常见且可能负面影响结局,需进一步研究安全有效剂量。

要点

  • 356例病毒性肝炎相关急性肝衰竭患者中57.5%有对乙酰氨基酚使用证据,24%为高或中等暴露。
  • 高暴露组死亡率51.6%、无移植生存率22.6%,在四组中分别最高和最低。
  • 高暴露组与无暴露组的死亡率及无移植生存率比较未达统计学显著差异。

核心结论

  • 在病毒性肝炎相关急性肝衰竭中,对乙酰氨基酚使用常见,与很少或无暴露相比可能负面影响结局。
  • 作者认为需要对病毒性肝炎患者使用对乙酰氨基酚的最安全有效剂量开展前瞻性研究。

研究设计与样本

  • 前瞻性多中心队列研究,纳入356例符合病毒性肝炎(甲型、乙型、EB病毒、单纯疱疹病毒)并导致急性肝衰竭(急性起病后肝性脑病、国际标准化比值≥1.5)或急性肝损伤(国际标准化比值>2.0、无肝性脑病)的患者。
  • 通过对乙酰氨基酚摄入史、血清对乙酰氨基酚水平或对乙酰氨基酚-CYS加合物检测评估暴露,按暴露水平分为高、中、低和无暴露组。

主要发现

  • 356例患者中205例(57.5%)有对乙酰氨基酚使用证据,87例(24%)为高或中等暴露。
  • 高/中等暴露组的转氨酶和胆红素水平类似对乙酰氨基酚与病毒混合性肝损伤。
  • 高暴露组、中等暴露组、低暴露组和无暴露组的死亡率分别为51.6%、21.4%、28.8%和30.5%,高暴露组最高。
  • 高暴露组、中等暴露组、低暴露组和无暴露组的无移植生存率分别为22.6%、44.6%、41.5%和40.4%,高暴露组最低。
  • 高暴露组与无暴露组的死亡率和无移植生存率具体比较,即使调整基线患者特征差异后,仍未达统计学显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Acute viral hepatitis (AVH) comprises 11% of acute liver failure (ALF) in North America while acetaminophen (APAP) toxicity represents 46%. The use of APAP to treat prodromal hepatitis symptoms is common. It is unknown if concurrent APAP use impacts liver injury in AVH-induced ALF. METHODS: In this prospective, multicenter cohort study, 356 patients meeting criteria for AVH including hepatitis A, B, Epstein-Barr virus, and herpes simplex virus, all leading to ALF (hepatic encephalopathy after acute illness, international normalized ratio ≥1.5), or acute liver injury (acute liver injury, international normalized ratio >2.0, no hepatic encephalopathy) were reviewed for evidence of APAP use: APAP ingestion history or measurement of serum APAP level or APAP-CYS adducts, a specific biomarker released into blood with APAP injury. Patients were grouped by APAP exposure level, from high (measurable APAP levels or toxic APAP-CYS), medium (therapeutic APAP-CYS), low (history of APAP ingestion only and/or barely detectable APAP-CYS), or no exposure recorded. RESULTS: Two hundred five of 356 patients (57.5%) with AVH-ALF had evidence of APAP use: 87 out of 356 (24%) demonstrated high or medium exposures. The aminotransferase and bilirubin levels of high/medium group resembled a mixed APAP-viral injury. Mortality was the highest (51.6%, 21.4%, 28.8%, and 30.5%), and transplant-free survival was the lowest (22.6%, 44.6%, 41.5%, and 40.4%) in the high exposure group compared with medium, low, and no exposure groups. However, the specific comparisons of mortality and transplant-free survival between the high exposure and no exposure groups were not statistically different even after adjusting for baseline patient characteristics differences. DISCUSSION: APAP use in AVH-ALF is common and may negatively impact outcomes compared with little or no APAP exposure. Prospective studies of the safest and effective dose of APAP to use in patients with AVH are needed.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Lee WM, Barnard C, Rule JA, et al. Association of Acetaminophen (Paracetamol) Use With Severity and Outcomes in Patients With Viral Hepatitis-Associated Acute Liver Failure. Am J Gastroenterol. 2024. PMID: 38994834. doi:10.14309/ajg.0000000000002941

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。